Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798937 | 0.94 | PIK3CG (0.44) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799317 | 0.91 | LMNA (0.43) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799137 | 0.90 | PIK3CG (0.42) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799347 | 0.87 | GCK (0.48) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL798678 | 0.87 | PIK3CG (0.47) | PIK3CGLMNAALDH1A1JAK2 | |
| SCHEMBL798962 | 0.86 | P2RY1 (0.43) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799355 | 0.86 | P2RY1 (0.43) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799077 | 0.86 | SLC27A1 (0.45) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799238 | 0.84 | LMNA (0.44) | PIK3CGLMNAMEN1KMT2AP2RY1 | |
| SCHEMBL799299 | 0.84 | PIK3CG (0.62) | PIK3CGLMNAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | PIK3CG 16/4885LMNA 4258/4885MEN1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.